Section 03 · Monograph

Benztropine

Reviewed Nov 2026FDA label

CogentinAnticholinergic

Indications

Adjunctive therapy in all forms of parkinsonismFDA-labeled
Control of extrapyramidal disorders (except tardive dyskinesia) due to neuroleptic (antipsychotic) drugs, including acute dystonic reactionsFDA-labeled

Anticholinergic (antimuscarinic) agent with additional antihistaminic properties
Central anticholinergic activity approximately equal to atropine in isolated tissue preparations, helping rebalance striatal cholinergic/dopaminergic tone in parkinsonism and drug-induced extrapyramidal states

Parkinsonism: initiate 0.5–1 mg at bedtime; increase gradually in increments of 0.5 mg every 5–6 days as needed and tolerated, up to a maximum of 6 mg/day; usual maintenance range 1–2 mg/day
Drug-induced extrapyramidal disorders: 1–4 mg once or twice daily orally (or IM/IV); acute dystonic reactions often respond to a single 1–2 mg IM or IV dose
Elderly patients generally cannot tolerate large doses — individualize dosing and titrate slowly

Pediatric use (>3 years): use with caution due to atropine-like effects; not recommended under 3 years

Hypersensitivity to benztropine mesylate
Children under 3 years of age (increased susceptibility to atropine-like adverse effects)
Should probably not be used in angle-closure glaucoma

Concurrent use with phenothiazines and haloperidol may increase risk of paralytic ileus, hyperthermia/heat stroke, and toxic psychosis
Additive anticholinergic effects with tricyclic antidepressants and other anticholinergic agents
Additive CNS depressant effects with alcohol and other CNS depressants
Caution with other drugs that reduce sweating or predispose to hyperthermia

Dry mouth (may require dose reduction if severe), nausea, vomiting, constipation
Tachycardia
Blurred vision, dilated pupils, increased intraocular pressure
Urinary hesitancy/retention, dysuria
Toxic psychosis, confusion, memory impairment, visual hallucinations, depression, numbness of fingers — especially with large doses or in susceptible patients
Anhidrosis (decreased sweating), which can lead to hyperthermia/heat stroke — severe anhidrosis and fatal hyperthermia have occurred, particularly in hot weather, with concurrent atropine-like drugs, or in patients with CNS disease
Paralytic ileus (rare but serious)
May aggravate tardive dyskinesia; not recommended for treatment of tardive dyskinesia

Monitor mental status and cognition, particularly with dose increases and in elderly patients
Assess for heat intolerance/anhidrosis; counsel patients to avoid excessive heat exposure and strenuous activity in hot weather
Monitor bowel function for constipation/paralytic ileus
Monitor for urinary retention, especially in men with prostatic hypertrophy
Cumulative drug action requires continued clinical supervision over time
Periodically reassess ongoing need, especially when treating transient drug-induced extrapyramidal symptoms
Watch for tachycardia

Pregnancy: safety in human pregnancy has not been established per labeling
Lactation: labeling does not provide specific data on excretion into human milk or effects on the nursing infant
Use during pregnancy/lactation only if clearly needed, weighing maternal benefit against potential fetal/infant anticholinergic exposure